Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV

BACKGROUND: Chemotherapy plus immune-checkpoint inhibitor (CTx+ICI) therapy has become the preferred 1st line treatment in patients with metastatic NSCLC without oncogenic driven mutations. However, the optimal subsequent 2nd line treatment is not defined and several alternatives exist. The purpose...

Descripción completa

Detalles Bibliográficos
Autores principales: Brueckl, Wolfgang M., Reck, Martin, Rittmeyer, Achim, Kollmeier, Jens, Wesseler, Claas, Wiest, Gunther H., Christopoulos, Petros, Stenzinger, Albrecht, Tufman, Amanda, Hoffknecht, Petra, Ulm, Bernhard, Reich, Fabian, Ficker, Joachim H., Laack, Eckart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350088/
https://www.ncbi.nlm.nih.gov/pubmed/34430350
http://dx.doi.org/10.21037/tlcr-21-197

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350088/
https://www.ncbi.nlm.nih.gov/pubmed/34430350
http://dx.doi.org/10.21037/tlcr-21-197

Ejemplares similares